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Recently the Centre for Disease Control suggested that ‘pre-
cision public health’ presents significant opportunities to im-
prove the health of the population,1 but what does this
concept add and does it live up to the hype? The promise is
that by harnessing the power of Big Data, particularly geno-
mic data, we may indeed see early gains in public health as a
result of ‘more-accurate methods for measuring disease,
pathogens, exposures, behaviors, and susceptibility’ to guide
targeted prevention strategies.2 However, the term ‘precision
public health’ is susceptible to misinterpretation. Long before
Big Data in the form of personalized genetic and epigenetic
profiling arrived, much public health screening and preven-
tion strategy was premised on varying degrees of targeting
and stratification, so this is nothing new. Nevertheless,
others in the UK have used analogous terms such as ‘person-
alized prevention’ or ‘personalized public health’, represent-
ing them as part of an urgent agenda in which we must ‘reap
the benefits of the genomic revolution’.3
The purpose of this article is therefore to highlight
some of the evidentiary and philosophical challenges for
the concept of ‘precision public health’ which have not
been exposed to sufficient scrutiny. It is also to argue for
a more considered focus beyond the genome, lest we ca-
reer headlong towards a diversion of resources, away
from what really matters, to the detriment of population
health. To do this, we structure our critique by aligning it
with the so-called population perspective on precision
medicine (i.e. the ‘P4 approach’), namely that precision
public health should aim to be Predictive, Preventive,
Personalized and Participatory.4 The advantage of taking
this approach is that whereas it focuses on the key dimen-
sions and parameters of the decisions that could help im-
prove care both for individuals and populations, it has
gained traction among precision medicine proponents
themselves. Thereafter we return to the more philosophi-
cal and ethical arguments that should remind us of a big-
ger picture and the trade-offs that we might be making by
investing in ‘precision public health’.
P1
The promise is that billions of data points will allow pre-
diction of the future clinical needs of each patient, with a
huge emphasis on how personal genomic and other ‘omics’
data, linked to population health datasets, might improve
currently available prediction algorithms for chronic dis-
ease. The central idea here is that access to personalized ge-
netic data might improve identification of higher-risk
individuals and subsequently guide their lifestyle choices.5
Although there are undoubted public health benefits to
harnessing population-level ‘big data’ to inform policy and
evaluation, as epitomized by data linkage in the Nordic
countries, risk stratification approaches are already well
developed in clinical practice and public health on the basis
of established risk factors. Evidence of the added predictive
value of genetic markers is currently limited,6 but the
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inconvenient truth in the risk prediction industry is that we
are predicting outcomes for groups of people like our pa-
tient—we are not predicting the outcome for an individual.
On a very trite level of course, the outcome for any individ-
ual is binary, but there is a professional obligation to en-
sure that disease risks and chances of treatment benefit are
communicated more effectively, made all the more chal-
lenging because of the enduring statistical illiteracy of
many clinicians and patients.7
Predicting who will benefit from a particular intervention
or change in behaviour at the individual level is challenging.
An elegant demonstration of this notion appeared in a re-
cent study by Finegold et al.,8 that used Monte Carlo simu-
lation to evaluate how cardiovascular prevention benefits,
in terms of life expectancy gains, might be distributed across
a target group, dependent on their age, blood pressure, cho-
lesterol or smoking habit. The authors showed that even for
individuals starting with identical baseline risk, the out-
comes are far from uniform, with a small unpredictable mi-
nority of people having dramatic gains, far more than the
average for their risk stratum.8 Furthermore, for a risk fac-
tor or risk marker to serve as a useful discriminatory tool at
the individual level, we need relative risks or odds ratios
much greater than usually seen in epidemiology, greater
than 50 or so.9 But in addition to this, the uncomfortable
fact for companies who want to sell you your genetic pro-
file, is that the predictive capacity of genetic variants is de-
termined by the prevalence of the factors that interact with
them, and so we need to question the portability of even the
newer prediction engines driven by genetic data, at least as
far as the personalization of prevention is concerned.10
P2 / P3
Setting aside for a moment the challenges to developing bet-
ter prediction engines, their use is premised on offering ‘per-
sonalized’ risk information to guide lifestyle choices and
tailored prevention strategies (the second and third ‘P’s in
the P4 approach). Unfortunately, we have little basis for op-
timism when we consider the evidence—providing genetic
information to individuals has negligible impact on behav-
iour. In their updated 2016 systematic review, Hollands
et al.11 comprehensively assessed the impact of providing
DNA-based estimates of disease risk on health behaviours
and motivation to change them, ultimately concluding that
our expectations for such effects were not supported by the
evidence. Hollands et al.12 are among a growing number of
psychologists who doubt the utility of many current psycho-
logical theories of health behaviour change which privilege
the reflective self and individual agency over more
unconscious processes. Others go further and believe that
behaviour change is characterized by highly non-linear
phenomena, sensitive to initial conditions, and is best under-
stood through the lens of complexity theory,13 but a problem
for individual-level personalization is the fact that giving peo-
ple ever more refined risk information seems to have little im-
pact on behaviour and of course could cause harm.
We return to the place of individual agency and poten-
tial harms later, but one plausible conclusion that arises
from this evidence might be that the risks have not been
communicated properly. The controversy surrounding a
paper from Tomasetti and colleagues14 in 2015, which was
reported to infer that getting cancer was ‘a matter of
luck’,15 testifies to the fact that communicating the distinc-
tion between aleatory uncertainty (the natural stochastic
randomness in a process) and epistemic uncertainty (the
scientific uncertainty in the model of a process due to lim-
ited data and knowledge), is subtle to many scientists, let
alone the general public. The difference echoes Geoffrey
Rose’s distinction between the causes of individual cases
and the causes of incidence in populations. Cardiovascular
risk prediction algorithms are used to inform patients of
the chance that they will have a heart attack within the
next 10 years, though at an individual level the truth is
that no one knows whether a particular patient will experi-
ence an event or not. To address this, some psychologists
have endeavoured to improve risk communication for
health behaviour change by more accurately conveying
the random component of risk at the individual level,16
using animation of random avatars in a Cates plot.17
Unfortunately, at least in the context of cardiovascular risk,
this more progressive and honest way of conveying the risks
resulted in even lower behaviour change intentions.15
P4
The final P (Participatory) from the P4 personalized medi-
cine mantra connotes the desire to fully involve the patient
(or in our case, a healthy person) in making lifestyle
choices. Now although a much greater research effort has
so far gone into uncovering the physiological ways to per-
sonalized prevention (with genotypes and biomarkers),
an equally valid approach to personalization is to better
understand patient preferences. A great example of the
importance of this was offered by Taksler et al.18 who ap-
praised the effectiveness of a variety of preventive interven-
tions and the time required for the benefits to be realized.
They were able to rank the order of suitability for these
interventions (in terms of gain in life expectancy) for a pair
of very similar men (Bill and Adam), only one of whom
had diabetes, but whose other risk factors were compara-
ble. After a detailed analysis of the evidence, it turned out
that lowering cholesterol and blood pressure might be
more important for Bill than for Adam, whereas losing
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weight would gain more life expectancy for Adam. The
point is that seldom have insights about individual prefer-
ences (which were not overtly solicited for Bill or Adam)
been brought sufficiently into focus (for risk and benefits)
for Personalized Prevention, and they may well over-
shadow the magnitude of the effects of any new molecular
markers. Pravettoni and Gorini19 have argued that a
P4 paradigm is inadequate if it does not also consider indi-
vidual Psychology, advocating instead for a ‘P5’ approach
that accounts for the way patients may make differing
judgments of risk and benefits (which the Taksler study18
had not attempted). A similar perspective is offered by
Rogowski et al.20 who have argued that treatment options
could be tailored based upon on a more nuanced assess-
ment of patients’ benefit-risk preferences and tolerability
thresholds elicited through ‘Discrete Choice Experiments’.
In this context, better assessment and communication of
the potential harms of providing genetic information to
patients and the general public are required, discouraging
premature use of technologies with little evidence of health
benefit, which potentially pose significant health and social
risks.21,22
The Importance of Social Context
Now we have highlighted some specific empirical chal-
lenges to the P4/P5 approach to personalized prevention,
but perhaps they are secondary to more fundamental philo-
sophical and ethical problems. A key issue is the tendency
for the personalization agenda to further entrench the indi-
vidualization of risk, diverting public policy focus away
from the upstream determinants of population health.
Some leading scientists in our field have called for a
move away from ‘risk factor’ epidemiology, to one that
embraces a more nuanced complex systems perspective.
Francis Galton’s Quincunx, which you see most days in
the mechanism behind ‘The Tipping Point’ on daytime TV
(see Box 1 and Figure 1), provides an example of how
emergent phenomena arise as result of such complex sys-
tems. What structures the distribution generated by the
Quincunx is not the innate qualities of the ‘elements’ them-
selves but the features of both the funnel and the pins—both
their shape and their placement. Together, these structural
features determine which pellets can (or cannot) pass
through the pins and, for those that do, their possible
pathways. Personalized public health risks placing too much
Box 1. Galton’s Quincunx.
Sir Francis Galton invented the Quincunx, which demonstrates how a normal distribution can be generated from a ran-
dom process. Spherical beads or marbles are funnelled into the top where they collide with an array of pins, bouncing
either left or right after each collision, finally collected into wells at the bottom. With the pins organized as per the fig-
ure, the height of the balls in each well generates a normal distribution. About 100 years later, physicists were able to
build two models of the Quincunx, one designed to generate the normal distribution and the other to generate the log
normal distribution, by changing the arrangement of the pins. A simulation of the Quincunx is available at[http://www.
mathsisfun.com/data/quincunx.html].
Figure 1. Galton’s Quincunx. Sir Francis Galton invented the Quincunx,
which demonstrates how a normal-distribution can be generated from a
random process. Spherical beads or marbles are funnelled into the top
where they collide with an array of pins, bouncing either left or right after
each collision, finally collected into wells at the bottom. With the pins
organised as per the figure, the height of the balls in each well generates a
normal distribution. About 100 years later physicists were able to build
two models of the Quincunx, one designed to generate the normal distri-
bution and the other to generate the log normal distribution, by changing
the arrangement of the pins. A simulation of the Quincunx is available
here: http://www.mathsisfun.com/data/quincunx.html. This file is licensed
under the Creative Commons Attribution-Share Alike 3.0 Unported li-
cense. Source: https://commons.wikimedia.org/wiki/File:Galton_Box.svg.
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emphasis on the elements cascading through the Quincunx
(that is, for personalized public health, the people and their
personal genetic and molecular profiles), rather than the
system generating the distribution itself. As Krieger remarks:
Such an understanding of ‘structured chances’ is at odds
with explanations of population difference premised
solely on either determinism or chance, but forces us to
consider the humanly engineered social systems . . . that
give rise to the social stratification of disease risk.23
Risk stratification and prediction models for poor child
health and development outcomes have shown that mater-
nal demographic, income and health behaviour data that
can be easily collected at birth are the best predictors of
longer-term outcomes.24–27 Furthermore, area deprivation
has also been shown to significantly modify the perfor-
mance of cardiovascular risk prediction models in adults.28
Using the elegantly simple example of the Broad Street
pump, Khoury and Ioannidis suggest that a better use of
routinely collected population data on upstream determi-
nants of the distribution of disease is likely to be more
fruitful than ‘omics’ data for improving risk prediction at
individual and population levels.29 So when the Centers
for Disease Control and Prevention (CDC) see the opportu-
nity of genomics and precision public health to pave the
way for enhancing our understanding of the genetic and
epigenetic origins of inequalities,1,30 they seem to us to
rather miss the point.
A false dichotomy
Calls for a greater focus on upstream determinants in the
Big Data enterprise are by no means new, but Diez Roux
et al.31 highlight both the individual and the population
benefits including: (i) enabling greater precision in diagno-
sis and improved treatment (through for example im-
proved risk stratification and greater attention to patient
context in treatment decisions); (ii) detecting patients with
social or behavioural risk factors that, if addressed, might
lower disease burden and improve management and recov-
ery; and (iii) improving the capacity of health systems to
tailor services to the needs of the population they serve.
However, two further examples highlight how misguided
it might be to try to create a false dichotomy between ‘per-
sonalized’ and ‘population-based’ approaches to preven-
tion. Krypidemos and colleages, using a microsimulation
approach, show that combining structural population-
wide interventions with individual screening in the most
deprived areas is most likely to maximize both
effectiveness and equity of primary cardiovascular (CVD)
prevention.32 Beheshti et al.,33 on the other hand, using an
‘Agent Based Modelling’ approach, show that targeting
obesity interventions based only on individual characteris-
tics is less effective at the population level than when the
‘invisible’ influence of social norms and social networks is
taken into account.
Many commentators have expressed concerns that
tailoring treatments to patients based on their individual
genomes may lead to increasing inequality in human
health.34–38 Some of the earlier discourse in the USA about
the impact of personalized medicine and personalized
prevention on socioeconomic inequalities has focused dis-
proportionately on differential access to personalized med-
icine.39,40 More advantaged social groups may be more
likely to benefit from the targeted development, uptake,
affordability and access to personal genomic and pharma-
cogenetic testing technologies.41–44 For example, in the
context of breast and lung cancer screening and treatment,
poorer Black and ethnic minority groups are less likely to
be recruited into trials or have potential genetic risk
markers identified, and they are less likely to access new
therapies when these are developed.34,35 It seems to us na-
ively optimistic to imagine that interventions that rely on
individual agency, behaviour change and compliance with
treatment will have much impact on health inequalities,
and they may even widen them.45
Thus if we are to reduce inequalities and maximize the
benefits to individuals and populations, a whole-system
and upstream approach to prevention should be combined
with the so-called ‘personalized’ approach.32 However, the
increasing burden of chronic ill health in adulthood, and
the stark inequalities in healthy life expectancy in countries
such as the UK, are partly because we have not successfully
embedded and operationalized such approaches to
addressing the social determinants of health across policy.
There has long been a woeful mismatch in health and sci-
entific funding favouring high-tech solutions to problems
that could be prevented by allocating funding to addressing
the wider social determinants of health over the life course.
Despite the 5-year forward view for the NHS in England
suggesting that a ‘radical upgrade in prevention and public
health’ is required, only about 4% of the NHS budget is
spent on prevention;46 and prevention research receives
about 5% of all public spend on health research.47
Channelling limited resources into developing greater num-
bers of expensive treatments and diagnostic tools targeted
at small segments of the population can only exacerbate
this situation and divert attention from the bigger picture,
namely what are likely to be more effective and ethical
ways to improve population health and narrow inequal-
ities. In this context, the contribution of personalized/strat-
ified approaches for population health and health
inequalities remains unclear, and risks diversion of both fo-
cus and resources away from the big picture.
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